Coronavirus Disease 2019 Temperature Trajectories Correlate With Hyperinflammatory and Hypercoagulable Subphenotypes.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
01 02 2022
Historique:
entrez: 31 1 2022
pubmed: 1 2 2022
medline: 15 2 2022
Statut: ppublish

Résumé

Body temperature trajectories of infected patients are associated with specific immune profiles and survival. We determined the association between temperature trajectories and distinct manifestations of coronavirus disease 2019. Retrospective observational study. Four hospitals within an academic healthcare system from March 2020 to February 2021. All adult patients hospitalized with coronavirus disease 2019. Using a validated group-based trajectory model, we classified patients into four previously defined temperature trajectory subphenotypes using oral temperature measurements from the first 72 hours of hospitalization. Clinical characteristics, biomarkers, and outcomes were compared between subphenotypes. The 5,903 hospitalized coronavirus disease 2019 patients were classified into four subphenotypes: hyperthermic slow resolvers (n = 1,452, 25%), hyperthermic fast resolvers (1,469, 25%), normothermics (2,126, 36%), and hypothermics (856, 15%). Hypothermics had abnormal coagulation markers, with the highest d-dimer and fibrin monomers (p < 0.001) and the highest prevalence of cerebrovascular accidents (10%, p = 0.001). The prevalence of venous thromboembolism was significantly different between subphenotypes (p = 0.005), with the highest rate in hypothermics (8.5%) and lowest in hyperthermic slow resolvers (5.1%). Hyperthermic slow resolvers had abnormal inflammatory markers, with the highest C-reactive protein, ferritin, and interleukin-6 (p < 0.001). Hyperthermic slow resolvers had increased odds of mechanical ventilation, vasopressors, and 30-day inpatient mortality (odds ratio, 1.58; 95% CI, 1.13-2.19) compared with hyperthermic fast resolvers. Over the course of the pandemic, we observed a drastic decrease in the prevalence of hyperthermic slow resolvers, from representing 53% of admissions in March 2020 to less than 15% by 2021. We found that dexamethasone use was associated with significant reduction in probability of hyperthermic slow resolvers membership (27% reduction; 95% CI, 23-31%; p < 0.001). Hypothermics had abnormal coagulation markers, suggesting a hypercoagulable subphenotype. Hyperthermic slow resolvers had elevated inflammatory markers and the highest odds of mortality, suggesting a hyperinflammatory subphenotype. Future work should investigate whether temperature subphenotypes benefit from targeted antithrombotic and anti-inflammatory strategies.

Identifiants

pubmed: 35100194
doi: 10.1097/CCM.0000000000005397
pii: 00003246-202202000-00006
pmc: PMC8796835
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Biomarkers 0
Dexamethasone 7S5I7G3JQL

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

212-223

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM072808
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA027396
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM104323
Pays : United States
Organisme : NIGMS NIH HHS
ID : K23 GM144867
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG068720
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM123193
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA051464
Pays : United States

Informations de copyright

Copyright © 2022 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Déclaration de conflit d'intérêts

Dr. Bhavani is supported by the American Thoracic Society and GlaxoSmithKline research grant in coronavirus disease 2019 and by National Institutes of Health (NIH)/National Institute of General Medical Sciences (NIGMS) K23GM144867. Dr. Maier is supported by NIH/National Center for Advancing Translational Sciences UL1TR002378. Dr. Churpek is supported by NIGMS (R01GM123193), Department of Defense (W81XWH-21-1-0009), National Institute on Aging (R21 AG068720), and National Institute on Alcohol Abuse and Alcoholism (R01 DA051464-01); he has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients and has received research support from EarlySense (Tel Aviv, Israel). Dr. Coopersmith is supported by funding from the NIH (GM072808, GM104323, AA027396). Drs. Bhavani, Parker, Holder, Kamaleswaran, Churpek, and Coopersmith received support for article research from the NIH. Drs. Parker’s, Kamaleswaran’s, Wang’s, Churpek’s, and Coopersmith’s institutions received funding from the NIH. Dr. Holder received funding from Baxter International. Dr. Wang’s institution received funding from The Petit Institute Faculty Fellow Fund, the Amazon Faculty Research Fellowship, The Wallace H. Coulter Distinguished Faculty Fellow Award, the Georgia Institution of Technology, and the National Science Foundation; she received support for article research from The Petit Institute Faculty Fellow, The Wallace H. Coulter Distinguished Faculty Fellow, and The Amazon Faculty Research Fellowship. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Références

World Health Organization: Novel Coronavirus (COVID-19) Situation. Available at: https://covid19.who.int/ . Accessed April 30, 2021
Tay MZ, Poh CM, Rénia L, et al.: The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20:363–374
Verhoef PA, Kannan S, Sturgill JL, et al.; For the B, Translational Science Committee of the Research Section for the Society of Critical Care M: Severe acute respiratory syndrome–associated coronavirus 2 infection and organ dysfunction in the ICU: Opportunities for translational research. Crit Care Explor. 2021; 3:e0374
Rello J, Storti E, Belliato M, et al.: Clinical phenotypes of SARS-CoV-2: Implications for clinicians and researchers. Eur Respir J. 2020; 55:2001028
Lazzaroni MG, Piantoni S, Masneri S, et al.: Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2021; 46:100745
Gao YM, Xu G, Wang B, et al.: Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J Intern Med. 2021; 289:147–161
Wang X, Jehi L, Ji X, et al.: Phenotypes and subphenotypes of patients with COVID-19: A latent class modeling analysis. Chest. 2021; 159:2191–2204
Gutiérrez-Gutiérrez B, Del Toro MD, Borobia AM, et al.; REIPI-SEIMC COVID-19 group and COVID@HULP groups: Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: A multicentre cohort study. Lancet Infect Dis. 2021; 21:783–792
Azoulay E, Zafrani L, Mirouse A, et al.: Clinical phenotypes of critically ill COVID-19 patients. Intensive Care Med. 2020; 46:1651–1652
Sinha P, Calfee CS, Cherian S, et al.: Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: A prospective observational study. Lancet Respir Med. 2020; 8:1209–1218
Data Science Collaborative Group: Differences in clinical deterioration among three sub-phenotypes of COVID-19 patients at the time of first positive test: Results from a clustering analysis. Intensive Care Med. 2021; 47:113–115
Rodríguez A, Ruiz-Botella M, Martín-Loeches I, et al.; COVID-19 SEMICYUC Working Group: Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Crit Care. 2021; 25:63
Laing AG, Lorenc A, Del Molino Del Barrio I, et al.: A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020; 26:1623–1635
Liu J, Li S, Liu J, et al.: Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020; 55:102763
Jain A, Doyle DJ: Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020; 46:1494–1495
Bhavani SV, Carey KA, Gilbert ER, et al.: Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med. 2019; 200:327–335
Bhavani SV, Wolfe KS, Hrusch CL, et al.: Temperature trajectory subphenotypes correlate with immune responses in patients with sepsis. Crit Care Med. 2020; 48:1645–1653
Choron RL, Butts CA, Bargoud C, et al.: Fever in the ICU: A predictor of mortality in mechanically ventilated COVID-19 patients. J Intensive Care Med. 2021; 36:484–493
Ng DHL, Choy CY, Chan YH, et al.; National Centre for Infectious Diseases COVID-19 Outbreak Research Team: Fever patterns, cytokine profiles, and outcomes in COVID-19. Open Forum Infect Dis. 2020; 7:ofaa375
Tharakan S, Nomoto K, Miyashita S, et al.: Body temperature correlates with mortality in COVID-19 patients. Crit Care. 2020; 24:298
Nakamura K: Central circuitries for body temperature regulation and fever. Am J Physiol Regul Integr Comp Physiol. 2011; 301:R1207–R1228
Bhavani SV, Huang ES, Verhoef PA, et al.: Novel temperature trajectory subphenotypes in COVID-19. Chest. 2020; 158:2436–2439
Østergaard SD, Schmidt M, Horváth-Puhó E, et al.: Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: Side-effect or coincidence? Lancet. 2021; 397:1441–1443
Ekker MS, Verhoeven JI, Vaartjes I, et al.: Association of stroke among adults aged 18 to 49 years with long-term mortality. JAMA. 2019; 321:2113–2123
The RECOVERY Collaborative Group: Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020; 384:693–704
Linden A, Samuels SJ: Using balance statistics to determine the optimal number of controls in matching studies. J Eval Clin Pract. 2013; 19:968–975
Elze MC, Gregson J, Baber U, et al.: Comparison of propensity score methods and covariate adjustment: Evaluation in 4 cardiovascular studies. J Am Coll Cardiol. 2017; 69:345–357
Desai RJ, Franklin JM: Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: A primer for practitioners. BMJ. 2019; 367:l5657
Bikdeli B, Madhavan MV, Jimenez D, et al.; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function: COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75:2950–2973
Sadeghipour P, Talasaz AH, Rashidi F, et al.: Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. JAMA. 2021; 325:1620–1630
National Heart, Lung, and Blood Institute: ATTACC, ACTIV-4a & REMAP-CAP Multiplatform RCT: Results of Interim Analysis. 2021. Available at: https://nhlbi-connects.org/documents/mpRCT%20Interim%20Presentation.pdf . Accessed March 30, 2021
Van Poucke S, Stevens K, Marcus AE, et al.: Hypothermia: Effects on platelet function and hemostasis. Thromb J. 2014; 12:31
Zhang JN, Wood J, Bergeron AL, et al.: Effects of low temperature on shear-induced platelet aggregation and activation. J Trauma. 2004; 57:216–223
Lindenblatt N, Menger MD, Klar E, et al.: Sustained hypothermia accelerates microvascular thrombus formation in mice. Am J Physiol Heart Circ Physiol. 2005; 289:H2680–H2687
Remy KE, Brakenridge SC, Francois B, et al.: Immunotherapies for COVID-19: Lessons learned from sepsis. Lancet Respir Med. 2020; 8:946–949
Remy KE, Mazer M, Striker DA, et al.: Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight. 2021; 5:e140329
Notz Q, Schmalzing M, Wedekink F, et al.: Pro- and anti-inflammatory responses in severe COVID-19-induced acute respiratory distress syndrome-an observational pilot study. Front Immunol. 2020; 11:581338
Jamilloux Y, Henry T, Belot A, et al.: Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020; 19:102567
Caricchio R, Gallucci M, Dass C, et al.; Temple University COVID-19 Research Group: Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis. 2021; 80:88–95
Manson JJ, Crooks C, Naja M, et al.: COVID-19-associated hyperinflammation and escalation of patient care: A retrospective longitudinal cohort study. Lancet Rheumatol. 2020; 2:e594–e602
Reddy K, Rogers AJ, McAuley DF: Delving beneath the surface of hyperinflammation in COVID-19. Lancet Rheumatol. 2020; 2:e578–e579
Zeng F, Huang Y, Guo Y, et al.: Association of inflammatory markers with the severity of COVID-19: A meta-analysis. Int J Infect Dis. 2020; 96:467–474
Pitre T, Jones A, Su J, et al.; COREG Investigators: Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: A retrospective cohort study. Intern Emerg Med. 2021; 16:1573–1582
Longobardo A, Snow TAC, Montanari C, et al.: COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- a retrospective observational study. J Crit Care. 2021; 62:46–48
Chen H, Xie J, Su N, et al.: Corticosteroid therapy is associated with improved outcome in critically ill COVID-19 patients with hyperinflammatory phenotype. Chest. 2021; 159:1793–1802
Ho KS, Narasimhan B, Difabrizio L, et al.: Impact of corticosteroids in hospitalised COVID-19 patients. BMJ Open Respir Res. 2021; 8:e000766

Auteurs

Sivasubramanium V Bhavani (SV)

Department of Medicine, Emory University, Atlanta, GA.
Emory Critical Care Center, Atlanta, GA.

Philip A Verhoef (PA)

Department of Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, HI.
Hawaii Permanente Medical Group, Honolulu, HI.

Cheryl L Maier (CL)

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA.

Chad Robichaux (C)

Department of Biomedical Informatics, Emory University, Atlanta, GA.

William F Parker (WF)

Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL.

Andre Holder (A)

Department of Medicine, Emory University, Atlanta, GA.
Emory Critical Care Center, Atlanta, GA.

Rishikesan Kamaleswaran (R)

Department of Biomedical Informatics, Emory University, Atlanta, GA.

May D Wang (MD)

Department of Biomedical Engineering, Georgia Tech, Atlanta, GA.

Matthew M Churpek (MM)

Department of Medicine, University of Wisconsin, Madison, WI.

Craig M Coopersmith (CM)

Emory Critical Care Center, Atlanta, GA.
Department of Surgery, Emory University, Atlanta, GA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH